


First Clinical Research Stock Index (FCRI)

Market Activity

FCRI gained 7% last month, while biotechs gained 5%, pharmas gained 0.3%, and the general market declined 4%. Ten FCRI stocks rose and three declined. Significant gainers included PAREXEL International (+37%) and ICON (+14%). There were no significant decliners.

Counting only the stocks that remain publicly traded, FCRI is essentially back where it started five years ago, as are pharmaceutical stocks.



Notes on Indices

- **First Clinical Research Index (FCRI)**. Calculated as the mean average percentage change from baseline, dividends excluded, adjusted for stock splits. In other words, the indices are not weighted for stock price or market capitalization. Prices are in local currencies. Index components may change from time to time based on new listings, mergers and other factors. Components include all 16 publicly traded clinical research stocks: Bio-Imaging Technologies (BITI), CMIC (Tokyo 2309), Covance (CVD), Datatrak International (DATA), Encorium Group (ENCO), EPS Co., Ltd. (Tokyo 4282), eResearchTechnology (ERES), eTrials Worldwide (ETWC), ICON (ICLR), Averion International (AVRO), Kendle International (KNDL), MDS Pharma Services (MDZ), Medidata (MDSO:US), PAREXEL International (PRXL), Pharsight (PHST), Phase Forward (PFWD), and PPD (PPDI).
- **S&P 500 Index (SPX)**. Capitalization-weighted representative sample of 500 mostly large-capitalization companies in leading industries of the U.S. economy.
- **S&P 500 Pharmaceutical Index (S5PHARX)**. Capitalization-weighted S&P 500 companies engaged in research, development or production of pharmaceuticals.
- **S&P 500 Biotechnology Index (S5BIOTX)**. Capitalization-weighted S&P 500 companies primarily involved in development, manufacturing or marketing of products based on advanced biotechnology research.

Stock and index prices are available at <http://www.bloomberg.com/> and <http://finance.yahoo.com/>.